Overview

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-12
Target enrollment:
Participant gender:
Summary
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen